tbuckley/cabot-search huggingface dataset:
Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
Authors: T Dosani, M Carlsten, I Maric, O Landgren
Journal: Blood Cancer Journal (2015)

Correction to: Blood Cancer Journal (2015) 5, e306; doi:10.1038/bcj.2015.32; published online 17 April 2015 Since the publication of this paper, the authors have noticed an error in the title. It should read 'The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies'.
Abstract B42: Targeting cancer cell CCR2 enhances synergistic immune surveillance in breast cancer
Authors: Miriam R. Fein, Xue-Yan He, Ana S. Almeida, Arnaud Pommier, Emilis Bružas, Anaïs Eberhardt, John Erby Wilkinson, Camila dos Santos, Mikala Egeblad
Journal: Cancer Research (2018)

Abstract High expression of the C-C chemokine receptor type 2 (CCR2) in tumor samples and serum correlates with poor prognosis in human breast cancer, which has sparked interest in targeting the CCR2 pathway for therapeutic benefit. Importantly, a human CCR2 inhibitor (PF-04136309) has been investigated in clinical trials, and is currently being studied in a phase 1b/2 trial for pancreatic cancer (NCT02732938). Previous studies have focused on the protumor effects of CCR2 signaling in inflammatory monocytes. However, CCR2 is also expressed in breast cancer cells, but its potential function in cancer cells is poorly understood. To determine the specific roles of CCR2 in cancer and host cells, respectively, we established an orthotopic breast cancer mouse model by injecting primary cancer cells from MMTV-PyMT; Ccr2+/+ or MMTV-PyMT; Ccr2-/- mice into the mammary glands of wide-type or Ccr2 null hosts. In this cancer model, deleting Ccr2 in host cells, including monocytes, did not alter tumor growth. However, when tumor cells had lost Ccr2, immune surveillance was much more efficient, with greater infiltration and expansion of cytotoxic CD8+ T cell lymphocytes (CTLs) that efficiently recognized and destroyed the cancer cells, resulting in significant inhibition of tumor growth. Consistently, the delayed tumor growth of Ccr2 null cancer cells was fully reversed when these same cancer cells were transplanted into athymic (immunodeficient) mice. The reduced growth of tumors derived from Ccr2-/- cancer cells was associated with upregulation of IFN-γ response genes and genes involved in MHC class I presentation, as well as decreased expression of checkpoint inhibitor PD-L1 in cancer cells. Finally, greater infiltration of CD103+ dendritic cells (DCs) in Ccr2-/- tumor microenvironment also contributed to increased CTL function by cross presentation. Taken together, our results show that CCR2-expressing breast cancer cells orchestrated global changes in the infiltration of CTLs and DCs, leading to effective immune suppression. This suggests that CCR2 may be an immunotherapeutic target in breast cancer. Citation Format: Miriam R. Fein, Xue-Yan He, Ana S. Almeida, Arnaud Pommier, Emilis Bružas, Anaïs Eberhardt, John Erby Wilkinson, Camila dos Santos, Mikala Egeblad. Targeting cancer cell CCR2 enhances synergistic immune surveillance in breast cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond; 2017 Sep 24-27; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(10 Suppl):Abstract nr B42.
Systemic treatments for high-risk localized prostate cancer
Authors: Géraldine Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthelemy, Jean-Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc-Olivier Timsit, Sébastien Vincendeau, Gilles Pasticier, Delphine Borchiellini
Journal: Nature Reviews Urology (2018)
Skin specialist is suspended for six months after secretly recording colleague’s consultations
Authors: Clare Dyer
Journal: BMJ (2018)

A cosmetic doctor has been suspended for six months after she secretly recorded a colleague’s patient consultations and then falsely told patients that the surveillance had been carried out with the General Medical Council’s (GMC) approval.

Natalie Blakely, who is “known by the media as the Skin Queen,” according to her biography on Facebook and Twitter, was medical director of the Light Touch Clinic in Weybridge, Surrey. She treated a celebrity clientele and was once voted “best doctor for Botox and fillers” by Tatler magazine.

She became involved in an acrimonious dispute with a co-director, Peter Forrester, who she believed was undercharging patients from his previous …
Urbanicity and Risk of Schizophrenia—New Studies and Old Hypotheses
Authors: Oleguer Plana-Ripoll, Carsten Bøcker Pedersen, John J. McGrath
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Morgellons Disease—Dredged Up From History and Customized
Authors: Christopher Chu
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Patient-related determinants of antibiotic use: a systematic review
Authors: V. Zanichelli, G. Tebano, I.C. Gyssens, V. Vlahović-Palčevski, A.A. Monnier, M. Stanic Benic, S. Harbarth, M. Hulscher, C. Pulcini, B.D. Huttner
Journal: Clinical Microbiology and Infection (2018)
Abstract #2048: SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.
Authors: Jutta Deckert, Yong Yi, Sharon Chicklas, Michele Mayo, Thomas Chittenden, Peter Park
Journal: Cancer Research (2009)

SAR650984 is a humanized anti-CD38 antibody, co-developed with sanofi-aventis, in pre-clinical development for the treatment of hematologic malignancies. We have shown previously that this antibody can function through multiple mechanisms of action  in vitro : apoptosis, complement-dependent cytolysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC) (ASH 2008 Abstract #2756). Here we report a comprehensive examination of CD38 expression and  in vitro  activities of SAR650984 against a panel of CD38-positive human tumor cells lines derived from different hematologic disease indications: non-Hodgkin\#8217;s lymphoma, multiple myeloma and leukemia. SAR650984 showed pro-apoptotic activity, as measured by Annexin-V staining, against seven of these cell lines: Daudi, Ramos, SU-DHL-8, Raji, Namalwa, Molp-8, and DND-41. The maximum percentage of Annexin-V positive cells ranged from 11% to 90% and EC50 values from 0.02 to 0.2 nM. In addition, SAR650984 mediated strong complement-dependent lysis against Daudi, Ramos, SU-DHL-8, Raji, Molp-8, LP-1, and DND-41 with a maximum percentage of specific lysis between 22% and 95% and EC50 values from 0.1 nM to 0.4 nM. Finally, SAR650984 exerted potent ADCC activity through purified human NK cells against all tumor cell lines tested. The maximum percentage of NK-mediated lysis by SAR650984 ranged from 23% to 100% depending on the cell line and the EC50 values were between 1 and 30 pM. CD38 expression levels, measured quantitatively by flow cytometry using the BD Quantibrite method, ranged from 60,000 to 823,000 antibodies bound per cell (ABC). Cell lines expressing the highest levels of CD38 were subject to the most potent CDC activity by SAR650984, suggesting a correlation between CD38 expression levels and  in vitro  CDC activity by SAR650984. No correlation was observed in this set of cell lines between the levels of antigen expression and apoptotic or ADCC activity. SAR650984 showed strong  in vivo  efficacy in a xenograft model derived from the Molp-8 multiple myeloma cell line against which it was active  in vitro . In an early stage Molp-8 model with palpable tumors, 8 of 10 animals remained tumor free through the end of the study after treatment with 40 mg/kg of SAR650984 twice weekly for 3 weeks. In conclusion, SAR650984 mediates pro-apoptotic, complement-mediated lysis and ADCC activity against a variety of cells lines derived from lymphoma, multiple myeloma and leukemia, and this potent  in vitro  activity translates into potent  in vivo  efficacy.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2048.
Former editor in chief of RCP journal is struck off for dishonesty
Authors: Clare Dyer
Journal: BMJ (2018)

A consultant endocrinologist who was appointed editor in chief of Clinical Medicine , the journal of the Royal College of Physicians (RCP), has been struck off the UK medical register for falsely claiming to be a fellow of the college.

Paul Grant had already been suspended for four months last September for several instances of dishonesty and research misconduct.12 As his suspension ended he was already facing new allegations relating to his use of the post-nominal FRCP in emails, letters to patients, and on NHS websites, which brought him before a second medical practitioners tribunal in Manchester.

Grant was editor of the British Journal of Diabetes in September 2016 when he applied for the post at …
Consider funding social care like the NHS, say policy experts
Authors: Gareth Iacobucci
Journal: BMJ (2018)

Long overdue reforms to social care in England should create either a better means tested system or one that is more like the NHS by being free at the point of use for those who need it, policy experts have advised.

In a joint report1 analysing options for changing the way social care is funded, the Health Foundation and the King’s Fund say that England is now at a clear “fork in the road” with regards to how to reform the sector.

Noting the lack of progress on reform from the current government, it says that ministers must not shirk big decisions in …
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?
Authors: Jessamy Bagenal, Nicola Roche, Gill Ross, Anna Kirby, David Dodwell
Journal: BMJ (2018)

### What you need to know

Ductal carcinoma in situ (DCIS) affects around 8000 women a year in the UK.1 Since the introduction of mammographic screening, the incidence of DCIS has increased and it now represents around 20% of all new screen detected breast cancers.2

DCIS is categorised into low, intermediate, and high grade based on histological features. Most cases of DCIS are treated with breast conserving surgery (BCS), often followed by whole breast radiotherapy (WBRT). An individual patient level meta-analysis (four randomised controlled trials, 3729 women) found that WBRT approximately halved the rate of ipsilateral DCIS or invasive recurrence at 10 years compared with no radiotherapy following BCS.3 However, WBRT can cause side effects such as impaired cosmesis, skin changes, and late cardiac toxicity4 Patients might also find WBRT inconvenient and expensive.

National Institute of Health and Care Excellence (NICE) guidelines recommend offering WBRT to all patients with DCIS treated by BCS.5 The European Society of Medical Oncology guidelines suggest that WBRT might be omitted in some low risk patients.6

However, observational studies done in the UK, US, and Europe note wide variations in the use of adjuvant radiotherapy in these patients.7 This variation possibly reflects uncertainty as to whether the benefits of WBRT are large enough to warrant the blanket use of adjuvant WBRT or whether WBRT can be safely omitted in a subset of lower risk patients.

In this article we discuss the evidence surrounding radiotherapy use in …
Association of Statin Use With Overall and Cancer Survival—Reply
Authors: Louise Emilsson, Xabier García-Albéniz, Miguel A. Hernan
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation
Authors: Maryam Aghighi, Ashok J. Theruvath, Anuj Pareek, Laura L. Pisani, Raphael Alford, Anne M. Muehe, Tarsheen K. Sethi, Samantha J. Holdsworth, Florette K. Hazard, Dita Gratzinger, Sandra Luna-Fineman, Ranjana Advani, Sheri L. Spunt, Heike E. Daldrup-Link
Journal: Clinical Cancer Research (2018)

Purpose: Tumor-associated macrophages (TAMs) in malignant tumors have been linked to tumor aggressiveness and represent a new target for cancer immunotherapy. As new TAM-targeted immunotherapies are entering clinical trials, it is important to detect and quantify TAM with noninvasive imaging techniques. The purpose of this study was to determine if ferumoxytol-enhanced MRI can detect TAM in lymphomas and bone sarcomas of pediatric patients and young adults.Experimental Design: In a first-in-patient, Institutional Review Board-approved prospective clinical trial, 25 pediatric and young adult patients with lymphoma or bone sarcoma underwent ferumoxytol-enhanced MRI. To confirm ferumoxytol enhancement, five pilot patients (two lymphoma and three bone sarcoma) underwent pre- and postcontrast MRI. Subsequently, 20 patients (10 lymphoma and 10 bone sarcoma) underwent ferumoxytol-enhanced MRI 24 to 48 hours after i.v. injection, followed by tumor biopsy/resection and macrophage staining. To determine if ferumoxytol-MRI can differentiate tumors with different TAM content, we compared T2* relaxation times of lymphomas and bone sarcomas. Tumor T2* values of 20 patients were correlated with CD68+ and CD163+ TAM quantities on histopathology.Results: Significant ferumoxytol tumor enhancement was noted on postcontrast scans compared with precontrast scans (P = 0.036). Bone sarcomas and lymphomas demonstrated significantly different MRI enhancement and TAM density (P < 0.05). Within each tumor group, T2* signal enhancement on MR images correlated significantly with the density of CD68+ and CD163+ TAM (P < 0.05).Conclusions: Ferumoxytol-enhanced MRI is immediately clinically applicable and could be used to stratify patients with TAM-rich tumors to immune-targeted therapies and to monitor tumor response to these therapies. Clin Cancer Res; 24(17); 4110-8. ©2018 AACR.
Personalizing therapy for atrial fibrillation: the role of stem cell and in silico disease models
Authors: Scott Barichello, Jason D Roberts, Peter Backx, Patrick M Boyle, Zachary Laksman
Journal: Cardiovascular Research (2018)

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with substantial morbidity. There is considerable inter-patient variability in the pathologic processes that promote AF, and this variability likely has a significant genetic basis. Clinically this is reflected by the observation that anti-arrhythmic drugs and interventional procedures have highly variable efficacy, and this highlights the need for adopting a more efficacious personalized approach. We explore recent advancements in both in silico and stem cell disease models that set the stage for a personalized approach. Specifically we highlight new mechanistic insights in AF; the future role of computational models in planning personalized ablation strategies; the potential role of stem cell models as a preclinical platform for drug development; and the potential to use gene-editing technology to create patient-specific stem cell models. Finally, we introduce the concept of integrating stem cell models with computational modelling to create a novel pipeline for patient-specific drug discovery and development.
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Authors: Guillem Clot, Pedro Jares, Eva Giné, Alba Navarro, Cristina Royo, Magda Pinyol, David Martín-Garcia, Santiago Demajo, Blanca Espinet, Antonio Salar, Ana Ferrer, Ana Muntañola, Marta Aymerich, Hilka Rauert-Wunderlich, Elaine S. Jaffe, Joseph M. Connors, Randy D. Gascoyne, Jan Delabie, Armando López-Guillermo, German Ott, George W. Wright, Louis M. Staudt, Andreas Rosenwald, David W. Scott, Lisa M. Rimsza, Sílvia Beà, Elías Campo
Journal: Blood (2018)

Key Points A new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.
Untangling the Factors Contributing to Functional Outcome in Schizophrenia—Reply
Authors: Silvana Galderisi, Armida Mucci, Mario Maj
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial
Authors: Bum Joon Kim, Eun-Jae Lee, Sun U Kwon, Jong-Ho Park, Yong-Jae Kim, Keun-Sik Hong, Lawrence K S Wong, Sungwook Yu, Yang-Ha Hwang, Ji Sung Lee, Juneyoung Lee, Joung-Ho Rha, Sung Hyuk Heo, Sung Hwan Ahn, Woo-Keun Seo, Jong-Moo Park, Ju-Hun Lee, Jee-Hyun Kwon, Sung-Il Sohn, Jin-Man Jung, Jose C Navarro, Dong-Wha Kang, Sun U Kwon, Juneyoung Lee, Dong-Wha Kang, Joung-Ho Rha, Jong-Moo Park, Yong-Seok Lee, Ju-Hun Lee, Yong-Jae Kim, Keun-Sik Hong, Kyung Ho Yu, Sung-Il Sohn, Seong Hwan Ahn, Jae-Kwan Cha, Man-Seok Park, Jong S Kim, Byung-Woo Yoon, Byung-Chul Lee, Cheong-Mo Nam, Ja-Seong Koo, Hyo-Seok Nam, Kwang-Yeol Park, Jong-Moo Park, Ju-Hun Lee, Dae-Hyun Kim, Joung-Ho Rha, Hyun-Wook Nah, Yong-Seok Lee, Yong-Jin Cho, Dong-Eog Kim, Moon-Ku Han, Kyung-Bok Lee, Seong Hyuk Heo, Ji Hoe Heo, Bum Joon Kim, Kyung-Hee Cho, Han-Young Kim, Young-Dae Kim, Ah-Hyun Cho, Kyeong-Yul Lee, Jin-Soo Lee, Jong-Ho Park, Woo-Keun Seo, Eung-Gyu Kim, Im-Seok Koh, Nak-Cheon Choi, Jee-Hyun Kwon, June Lee, Yang-Ha Hwang, Hee-Jeong Song, Byung-Soo Shin, June-Tae Kim, Soo-Joo Lee, Pil-Wook Chung, Seong-Heon Kim, June-Hong Lee, Dong-Ik Shin, Jin Kuk Do, Sang-Bong Lee, Young-Bae Lee, Bong-Goo Yoo, Sang Min Sung, Jin-Man Jung, Jeong-Wook Park, Tae-Kyung Lee, Jose C Navarro, Maria Cristina Z San Jos, Artemio Roxas, Raquel J Mallarl-Alvarez, Ma. Epifania V Collantes, Lawrence K.S WONG, Wing-Chi Fong, Tak Hong Tsoi, Ping Wing Ng, Eun-Jae Lee, Ji Sung Lee
Journal: The Lancet Neurology (2018)
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response
Authors: Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Seiji Sakata, Satoko Baba, Hideki Nakasone, Sumie Koike, Naoko Tsuyama, Akito Dobashi, Makoto Sasaki, Ryo Ichinohasama, Emi Takakuwa, Rie Yamazaki, Jun Takizawa, Takahiro Maeda, Miwako Narita, Koji Izutsu, Yoshinobu Kanda, Koichi Ohshima, Kengo Takeuchi
Journal: Leukemia (2018)
What’s hot that the other lot got
Authors: Erik Skyllberg
Journal: Thorax (2018)

Procalcitonin is an acute-phase reactant with improved discriminatory value for bacterial infection compared with traditional markers such as white cell count and C reactive protein. A meta-analysis performed by Schuetz et al ( Lancet Infect Dis 2018;18:95–107) assessed mortality and treatment failure in patients with an acute respiratory infection receiving procalcitonin- guided therapy versus a control group. The study included 6708 individual patients from 26 trials. Procalcitonin-guided therapy was associated with lower mortality (adjusted OR 0.83, 95% CI 0.70 to 0.99, P=0.037), shorter treatment duration (8.0±6.5 days vs 9.4±6.2 days, P<0.0001) and fewer antibiotic-associated side effects (16% vs 22%, P<0.0001). However, there was no significant reduction in risk of treatment failure (adjusted OR 0.90, 95% CI 0.80 to 1.01, P=0.068). These effects were consistent across clinical settings and types of infections. There was no significant improvement in the duration of intensive care unit or hospital stays. These data support the use of procalcitonin-guided management in respiratory infections in a range of clinical settings to reduce antibiotic use and may improve mortality.

Agusti et al …